04April

Rybelsus® (oral semaglutide) approved for the treatment of adults with type 2 di ... Read more

31March

Novo Nordisk A/S: Saxenda® demonstrated improvements in BMI and body weight in a ... Read more

26March

Resolutions from the Annual General Meeting of Novo Nordisk A/S ... Read more

16March

Novo Nordisk pauses the clinical trials investigating concizumab (anti-TFPI mAB) ... Read more

04April

Rybelsus® (oral semaglutide) approved for the treatment of adults with type 2 di ... Read more

30March

Novo Nordisk A/S - Share repurchase programme ... Read more

26March

Resolutions from the Annual General Meeting of Novo Nordisk A/S ... Read more

23March

Novo Nordisk A/S – Share repurchase programme ... Read more

06May

Financial statements for the first three months of 2020,

01July

Silent period,

06August

Financial statement for the first six months of 2020,

01October

Silent period,

 

 

 

Investors

Share information
 

SHARE Magazine


Get the latest SHARE Magazine

- news for you as an investor

 

Corporate reporting

Capital markets day


Capital Markets Day 2019 
- Webcast and presentations

 

Private shareholders


Shareholder tools and systems for private investors

 

Investor materials

Contact Investor Relations

Sign-up: Company announcements


Sign up and receive our company announcements

 

Financial results and events overview